{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:44:48Z","timestamp":1789454688994,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,25]],"date-time":"2008-10-25T00:00:00Z","timestamp":1224892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s12185-008-0186-0","type":"journal-article","created":{"date-parts":[[2008,10,23]],"date-time":"2008-10-23T23:56:57Z","timestamp":1224806217000},"page":"409-417","source":"Crossref","is-referenced-by-count":10,"title":["Current and future perspectives on the TARGET system: the registration system for Glivec\u00ae established by the JSH"],"prefix":"10.1007","volume":"88","author":[{"name":"and the TARGET Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsune","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Tsudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,25]]},"reference":[{"key":"186_CR1","unstructured":"Cancer Incidence in Five Countries, vol VIII, Parkin DM, et al., eds. IARC Press, Lyon, 2002."},{"key":"186_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004. doi: 10.1056\/NEJMoa022457 .","journal-title":"N Engl J Med"},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317. doi: 10.1056\/NEJMoa062867 .","journal-title":"N Engl J Med"},{"key":"186_CR4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or intereferon \u03b1 plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423\u201332. doi: 10.1056\/NEJMoa030513 .","journal-title":"N Engl J Med"},{"key":"186_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908\u201316. doi: 10.1038\/nm1446 .","journal-title":"Nat Med"},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038\u201342. doi: 10.1056\/NEJM200104053441402 .","journal-title":"N Engl J Med"},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpatz M, Giles F, O\u2019Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145:913\u201323.","journal-title":"Ann Intern Med"},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:867\u201380. doi: 10.1126\/science.1062538 .","journal-title":"Science"},{"key":"186_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351. doi: 10.1056\/NEJMoa055104 .","journal-title":"N Engl J Med"},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpatz","year":"2006","unstructured":"Talpatz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341. doi: 10.1056\/NEJMoa055229 .","journal-title":"N Engl J Med"},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","volume":"107","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;107:497\u20139. doi: 10.1182\/blood-2006-07-035493 .","journal-title":"Blood"},{"key":"186_CR12","doi-asserted-by":"crossref","unstructured":"Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2006 (Epub ahead of print).","DOI":"10.1182\/blood-2006-09-046888"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-008-0186-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0186-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:01:21Z","timestamp":1559437281000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-008-0186-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,25]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1007\/s12185-008-0186-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,25]]}}}